Latest Conference Articles

Ashraf Badros, MBCHB, discusses the addition of subcutaneous daratumumab to lenalidomide vs lenalidomide alone in newly diagnosed myeloma following ASCT.

The addition of fecal microbiota transplantation to pembrolizumab and axitinib raised the efficacy of the combination in metastatic renal cell carcinoma.

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.

The data are part of the largest reported cohorts of consecutive and uniformly treated real-world patients with newly diagnosed multiple myeloma.

Mezigdomide, tazemetostat, and dexamethasone demonstrated early efficacy signals in patients with refractory multiple myeloma.

Belantamab mafodotin plus KRd was associated with a manageable safety profile and deep responses in pretreated patients with multiple myeloma.

All patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.

Durcabtagene autoleucel generated responses with a tolerable safety profile in relapsed/refractory multiple myeloma.

Daratumumab plus VRd improved MRD-negativity rates in transplant-ineligible or -deferred, newly diagnosed multiple myeloma.

Daratumumab/lenalidomide maintenance increased MRD-negative conversion rates vs lenalidomide alone in newly diagnosed multiple myeloma after transplant.

Patients with newly diagnosed, transplant-eligible multiple myeloma achieved deep responses and MRD negativity with isa-KRd induction therapy.

Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.

Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.

Radium-223 prior to docetaxel improved quality of life and tolerability in patients with metastatic castration-resistant prostate cancer according to data from the RAPSON trial.

D-VRd induction and consolidation therapy displayed a PFS benefit vs VRd in high-risk subgroups of patients with newly diagnosed multiple myeloma.

Belantamab mafodotin-based combination appears to improve responses over time in those with transplant-eligible newly diagnosed multiple myeloma

Read about the early-phase sarcoma studies presented at the 2024 ESMO Congress that experts are keeping their eyes on.

Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.

Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.

The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.

Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.

Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

Lenvatinib plus pembrolizumab led to tumor responses regardless of mismatch repair–proficient status, histology, and prior adjuvant therapy.

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.

Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.

Neoadjuvant chemotherapy improved organ preservation in nasal and paranasal sinus squamous cell carcinoma.

Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Fianlimab plus cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma.